$PFE News

Pfizer Oncology Data At ASCO 2026 Reshapes Long Term Growth Story

Is Pfizer Inc. (PFE) Expanding Its Cancer Pipeline Through a Landmark Innovent Partnership?

Why Pfizer’s Current Price May Be Too Cheap to Ignore

Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock

Pfizer CEO Albert Bourla on the company's obesity drug pipeline

Pfizer CEO Albert Bourla on the company's oncology focus

Pfizer Oncology Deal And Lung Cancer Data Reshape Valuation Debate

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

The Evolving EGFR NSCLC Market: 8 Emerging Late-stage Therapies to Watch | DelveInsight

How S&P 500 Giant Pfizer Is Tackling Hard-To-Treat Cancers

Growing US reliance on Chinese biotechs prompts national security fears

Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

Pfizer Strikes Up To $10.5 Billion Deal With China's Innovent Biologics To Develop Next-Gen Cancer Therapies

Pfizer's $10.5 Billion Oncology Bet Sends Innovent Shares Surging

Pfizer Expands Oncology Pipeline in $10.5B Innovent Deal

Seven-Year Analysis from Pfizer’s LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer

Pfizer and Innovent Biologics sign $10.5B cancer drug deal

Pfizer and Innovent Biologics sign $10.5bn cancer drug development deal

Pfizer Announces Unprecedented 7-Yr Follow-Up Results From Phase 3 CROWN Trial Evaluating LORBRENA Vs XALKORI In People With ALK-Positive Advanced Or Metastatic NSCLC

Pfizer, Innovent strike $10B cancer drug deal